Update on the use of antibiotics in cutaneous surgery

Dermatologic Surgery

Volumn 31, Issue 8 PART 2, 2005, Pages 1068-1078

  Messingham, Michael J ^a   Arpey, Christopher J ^a  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMPICILLIN; ANTIBIOTIC AGENT; ANTIVIRUS AGENT; AZITHROMYCIN; BACITRACIN; CEFADROXIL; CEFALEXIN; CEFAZOLIN; CIMETIDINE; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; DICLOXACILLIN; ERYTHROMYCIN; LEVOFLOXACIN; MACROLIDE; PENICILLIN G; SULFADIAZINE SILVER; VANCOMYCIN;

ANAPHYLAXIS; ARGYRIA; ARTHROPLASTY; BACTEREMIA; BONE MARROW SUPPRESSION; BURN; CHEMOSURGERY; CONTACT DERMATITIS; CONTACT SENSITIVITY; DISEASE CLASSIFICATION; DRUG COST; DRUG SAFETY; DRUG USE; ENDOCARDITIS; HERPES; HUMAN; HYPERSENSITIVITY; INFECTION PREVENTION; INFECTION RISK; INFORMATION RETRIEVAL; JOINT PROSTHESIS; LEUKOPENIA; LIPOSUCTION; NONHUMAN; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSTHESIS INFECTION; REVIEW; SKIN FLAP; SKIN GRAFT; SKIN SURGERY; STEVENS JOHNSON SYNDROME; SURGICAL INFECTION; ANTIBIOTIC PROPHYLAXIS; PLASTIC SURGERY; SKIN TUMOR; WOUND INFECTION;

ANTIBIOTIC PROPHYLAXIS; HUMANS; MOHS SURGERY; RECONSTRUCTIVE SURGICAL PROCEDURES; SKIN NEOPLASMS; WOUND INFECTION;

EID: 24044488621     PISSN: 10760512     EISSN: 15244725     Source Type: Journal    
DOI: 10.1111/j.1524-4725.2005.31832     Document Type: Review

References (155)

1. Cohen ML. Emerging problems of antimicrobial resistance. Ann Emerg Med 1994;24:454-6.
2. Cohen PR, Kurzrock R. Community-acquired methicillin-resistant Staphylococcus aureus skin infection: an emerging clinical problem. J Am Acad Dermatol 2004;50:277-80.
3. Goldmann DA, Weinstein RA, Wenzel RP, et al. Strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganisms in hospitals. A challenge to hospital leadership. JAMA 1996;275:234-40.
4. Gross R, Morgan AS, Kinky DE, et al. Impact of a hospital-based antimicrobial management program on clinical and economic outcomes. Clin Infect Dis 2001;33:289-95.
5. Schito GC. Is antimicrobial resistance also subject to globalization? Clin Microbiol Infect 2002;8 Suppl 3:1-8.
6. Sensakovic JW, Smith LG. Oral antibiotic treatment of infectious diseases. Med Clin North Am 2001;85:115-23, vii.
7. Twomey C. Antibiotic resistance-an alarming health care issue. AORN J 2000;72:64-75.
8. Upton A, Lang S, Heffernan H. Mupirocin and Staphylococcus aureus: a recent paradigm of emerging antibiotic resistance. J Antimicrob Chemother 2003;51:613-7.
9. Scheinfeld N, Struach S, Ross B. Antibiotic prophylaxis guideline awareness and antibiotic prophylaxis use among New York State dermatologic surgeons. Dermatol Surg 2002;28:841-4.
10. George PM. Dermatologists and antibiotic prophylaxis: a survey. J Am Acad Dermatol 1995;33:418-21.
11. Rabb DC, Lesher JL Jr. Antibiotic prophylaxis in cutaneous surgery. Dermatol Surg 1995;21:550-4.
12. Haas AF, Grekin RC. Antibiotic prophylaxis in dermatologic surgery. J Am Acad Dermatol 1995;32:155-76.
13. Hirschmann JV. Antimicrobial prophylaxis in dermatology. Semin Cutan Med Surg 2000;19:2-9.
14. Stasko TCA. Surgical complications and optimizing outcomes. In: Bolognia JJJRP, editor. Dermatology. New York: Mosby; 2003. p. 2341-54.
15. Burke JP. Maximizing appropriate antibiotic prophylaxis for surgical patients: an update from LDS Hospital, Salt Lake City. Clin Infect Dis 2001;33 Suppl 2:S78-83.
16. Classen DC, Evans RS, Pestotnik SL, et al. The timing of prophylactic administration of antibiotics and the risk of surgical-wound infection. N Engl J Med 1992;326:281-6.
17. Nichols RL. Antibiotic prophylaxis in surgery. J Chemother 1989;1:170-8.
18. Cruse PJ, Foord R. A five-year prospective study of 23,649 surgical wounds. Arch Surg 1973;107:206-10.
19. Futoryan T, Grande D. Postoperative wound infection rates in dermatologic surgery. Dermatol Surg 1995;21:509-14.
20. Lilienfeld DE, Vlahov D, Tenney JH, McLaughlin JS. Obesity and diabetes as risk factors for postoperative wound infections after cardiac surgery. Am J Infect Control 1988;16:3-6.
21. Roth RR, James WD. Microbiology of the skin: resident flora, ecology, infection. J Am Acad Dermatol 1989;20:367-90.
22. Tabet JC, Johnson JT. Wound infection in head and neck surgery: prophylaxis, etiology and management. J Otolaryngol 1990;19:197-200.
23. Griego RD, Zitelli JA. Intra-incisional prophylactic antibiotics for dermatologic surgery. Arch Dermatol 1998;134:688-92.
24. Bencini PL, Galimberti M, Signorini M, Crosti C. Antibiotic prophylaxis of wound infections in skin surgery. Arch Dermatol 1991;127:1357-60.
25. Whitaker DC, Grande DJ, Johnson SS. Wound infection rate in dermatologic surgery. J Dermatol Surg Oncol 1988;14:525-8.
26. Dajani AS, Taubert KA, Wilson W, et al. Prevention of bacterial endocarditis. Recommendations by the American Heart Association. JAMA 1997;277:1794-801.
27. Geronemus RG, Mertz PM, Eaglstein WH. Wound healing. The effects of topical antimicrobial agents. Arch Dermatol 1979;115:1311-4.
28. Fielding G, Rao A, Davis NC, Wernigk N. Prophylactic topical use of antibiotics in surgical wounds: a controlled clinical trial using "polybactrin." Med J Aust 1965;17:159-61.
29. Halasz NA. Wound infection and topical antibiotics: the surgeon's dilemma. Arch Surg 1977;112:1240-4.
30. Forbes GB. Staphylococcal infection of operation wounds with special reference to topical antibiotic prophylaxis. Lancet 1961;ii:505-9.
31. Heisterkamp C III, Vernick J, Simmons RL, Motsumoto T. Topical antibiotics in war wounds: a re-evaluation. Mil Med 1969;134:13-8.
32. Langford JH, Artemi P, Benrimoj SI. Topical antimicrobial prophylaxis in minor wounds. Ann Pharmacother 1997;31:559-63.
33. Leyden JJ, Kligman AM. Rationale for topical antibiotics. Curtis 1978;22:515-8.
34. Watcher MA, Wheeland RG. The role of topical agents in the healing of full-thickness wounds. J Dermatol Surg Oncol 1989;15:1188-95.
35. Smack DP, Harrington AC, Dunn C, et al. Infection and allergy incidence in ambulatory surgery patients using white petrolatum vs bacitracin ointment. A randomized controlled trial. JAMA 1996;276:972-7.
36. Daly BM. Bactroban allergy due to polyethylene glycol. Contact Dermatitis 1987;17:48-9.
37. Eedy DJ. Mupirocin allergy in the setting of venous ulceration. Contact Dermatitis 1995;32:240-1.
38. Praz SM, de Torrente A, Zender H, et al. Toxic epidermal necrolysis after topical intranasal application of mupirocin. Infect Control Hosp Epidemiol 2003;24:459-60.
39. Zappi EG, Brancaccio RR. Allergic contact dermatitis from mupirocin ointment. J Am Acad Dermatol 1997;36:266.
40. Binnick AN, Clendenning WE. Bacitracin contact dermatitis. Contact Dermatitis 1978;4:180-1.
41. Dyck ED, Vadas P. Anaphylaxis to topical bacitracin. Allergy 1997;52:870-1.
42. Eedy DJ, McMillan JC, Bingham EA. Anaphylactic reactions to topical antibiotic combinations. Postgrad Med J 1990;66:858-9.
43. Fisher AA. Adverse reactions to bacitracin, polymyxin, and gentamicin sulfate. Cutis 1983;32:510-2, 520.
44. Gette MT, Marks JG Jr, Maloney ME. Frequency of postoperative allergic contact dermatitis to topical antibiotics. Arch Dermatol 1992;128:365-7.
45. Goh CE. Anaphylaxis from topical neomycin and bacitracin. Australas J Dermatol 1986;27:125-6.
46. Grandinetti PJ, Fowler JF Jr. Simultaneous contact allergy to neomycin, bacitracin, and polymyxin. J Am Acad Dermatol 1990;23:646-7.
47. Held JE, Kalb RE, Ruszkowski AM, DeLeo V. Allergic contact dermatitis from bacitracin. J Am Acad Dermatol 1987;17:592-4.
48. Jacob SE, James WD. From road rash to top allergen in a flash: bacitracin. Dermatol Surg 2004;30:521-4.
49. Knowles SR, Shear NH. Anaphylaxis from bacitracin and polymyxin B (Polysporin) ointment. Int J Dermatol 1995;34:572-3.
50. Lin FE, Woodmansee D, Patterson R. Near-fatal anaphylaxis to topical bacitracin ointment. J Allergy Clin Immunol 1998;101:136-7.
51. Maouad M, Fleischer AB Jr, Sherertz EF, Feldman SR. Significance- prevalence index number: a reinterpretation and enhancement of data from the North American contact dermatitis group. J Am Acad Dermatol 1999;41:573-6.
52. Marks JG, Belsito DV, DeLeo VA, et al. North American Contact Dermatitis Group patch test results for the detection of delayed-type hypersensitivity to topical allergens. J Am Acad Dermatol 1998;38:911-8.
53. Roupe G, Strannegard O. Anaphylactic shock elicited by topical administration of bacitracin. Arch Dermatol 1969;100:450-2.
54. Saryan JA, Dammin TC, Bouras AE. Anaphylaxis to topical bacitracin zinc ointment. Am J Emerg Med 1998;16:512-3.
55. Schechter JF, Wilkinson RD, Del Carpio J. Anaphylaxis following the use of bacitracin ointment. Report of a case and review of the literature. Arch Dermatol 1984;120:909-11.
56. Shackelford KE, Belsito DV. The etiology of allergic-appearing foot dermatitis: a 5-year retrospective study. J Am Acad Dermatol 2002;47:715-21.
57. Sherertz EF. Chronic finger dermatitis after trauma. Diagnosis: post-traumatic eczema with allergic contact dermatitis to neomycin, bacitracin, and topical corticosteroids. Arch Dermatol 1996;132:461, 464.
58. Sood A, Taylor JS. Bacitracin: allergen of the year. Am J Contact Dermatitis 2003;14:3-4.
59. Vale MA, Connolly A, Epstein AM, Vale MR. Bacitracin-induced anaphylaxis. Arch Dermatol 1978;114:800.
60. Zaki I, Shall L, Dalziel KE. Bacitracin: a significant sensitizer in leg ulcer patients? Contact Dermatitis 1994;31:92-4.
61. Fraki JE, Peltonen L, Hopsu-Havu VK. Allergy to various components of topical preparations in stasis dermatitis and leg ulcer. Contact Dermatitis 1979;5:97-100.
62. Marks JG Jr, Belsito DV, DeLeo VA, et al. North American Contact Dermatitis Group patch-test results, 1996-1998. Arch Dermatol 2000;136:272-3.
63. Pirila V, Forstrom E, Rouhunkoski S. Twelve years of sensitization to neomycin in Finland. Report of 1760 cases of sensitivity to neomycin and-or bacitracin. Acta Derm Venereol 1967;47:419-25.
64. Hoffmann S. Silver sulfadiazine: an antibacterial agent for topical use in burns. A review of the literature. Scand J Plast Reconstr Surg 1984;18:119-26.
65. Monafo WW, West MA. Current treatment recommendations for topical burn therapy. Drugs 1990;40:364-73.
66. Pruitt BA Jr, McManus AT, Kim SH, Goodwin CW. Burn wound infections: current status. World J Surg 1998;22:135-45.
67. Shirani KZ, Vaughan GM, Mason AD Jr, Pruitt BA Jr. Update on current therapeutic approaches in burns. Shock 1996;5:4-16.
68. Caffee HH, Bingham HG. Eeukopenia and silver sulfadiazine. J Trauma 1982;22:586-7.
69. Chan CK, Jarrett F, Moylan JA. Acute leukopenia as an allergic reaction to silver sulfadiazine in burn patients. J Trauma 1976;16:395-6.
70. Fisher NM, Marsh E, Lazova R. Scar-localized argyria secondary to silver sulfadiazine cream. J Am Acad Dermatol 2003;49:730-2.
71. Gamelli RL, Paxton TP, O'Reilly M. Bone marrow toxicity by silver sulfadiazine. Surg Gynecol Obstet 1993;177:115-20.
72. McKenna SR, Latenser BA, Jones LM, et al. Serious silver sulphadiazine and mafenide acetate dermatitis. Burns 1995;21:310-2.
73. Payne CM, Bladin C, Colchester AC, et al. Argyria from excessive use of topical silver sulphadiazine. Lancet 1992;340:126.
74. Degreef H, Dooms-Goossens A. Patch testing with silver sulfadiazine cream. Contact Dermatitis 1985;12:33-7.
75. Fuller FW, Engler PE. Leukopenia in non-septic burn patients receiving topical 1% silver sulfadiazine cream therapy: a survey. J Burn Care Rehabil 1988;9:606-9.
76. Thomson PD, Moore NP, Rice TL, Prasad JK. Leukopenia in acute thermal injury: evidence against topical silver sulfadiazine as the causative agent. J Burn Care Rehabil 1989;10:418-20.
77. Brown BM, Johnson JT, Wagner RL. Etiologic factors in head and neck wound infections. Laryngoscope 1987;97:587-90.
78. Cole RR, Robbins KT, Cohen JI, Wolf PF. A predictive model for wound sepsis in oncologic surgery of the head and neck. Otolaryngol Head Neck Surg 1987;96:165-71.
79. Johnson JT, Myers EN, Thearle PB, et al. Antimicrobial prophylaxis for contaminated head and neck surgery. Laryngoscope 1984;94:46-51.
80. Gilbert DN, Moellering RC, Sande MA. The Sanford guide to antimicrobial therapy. Hyde Park (VT): Antimicrobial Therapy, Inc.; 2003.
81. Brook I, Frazier EH. Aerobic and anaerobic bacteriology of wounds and cutaneous abscesses. Arch Surg 1990;125:1445-51.
82. Fine BC, Sheckman PR, Bartlett JC. Incision and drainage of soft-tissue abscesses and bacteremia. Ann Intern Med 1985;103:645.
83. Macfie J, Harvey J. The treatment of acute superficial abscesses: a prospective clinical trial. Br J Surg 1977;64:264-6.
84. Meislin HW, Lerner SA, Graves MH, et al. Cutaneous abscesses. Anaerobic and aerobic bacteriology and outpatient management. Ann Intern Med 1977;87:145-9.
85. Alster TS. Against antibiotic prophylaxis for cutaneous laser resurfacing. Dermatol Surg 2000;26:697-8.
86. Friedman PM, Geronemus RG. Antibiotic prophylaxes in laser resurfacing patients. Dermatol Surg 2000;26:695-7.
87. Gaspar Z, Vinciullo C, Elliott T. Antibiotic prophylaxis for full-face laser resurfacing: is it necessary? Arch Dermatol 2001;137:313-5.
88. Manuskiatti W, Fitzpatrick RE, Goldman MP, Krejci-Papa N. Prophylactic antibiotics in patients undergoing laser resurfacing of the skin. J Am Acad Dermatol 1999;40:77-84.
89. Mayhall CG, Polk RE, Haynes BW. Infections in burned patients. Infect Control 1983;4:454-9.
90. Mayhall CG. The epidemiology of burn wound infections: then and now. Clin Infect Dis 2003;37:543-50.
91. Ugburo AO, Atoyebi OA, Oyeneyin JO, Sowemimo GO. An evaluation of the role of systemic antibiotic prophylaxis in the control of burn wound infection at the Lagos University Teaching Hospital. Burns 2004;30:43-8.
92. 2 laser resurfacing infection rate with and without prophylactic antibiotics. Dermatol Surg 1999;25:857-61.
93. Lawrence JC. Burn bacteriology during the last 50 years. Burns 1992;18 Suppl 2:S23-9.
94. Maurice PD, Parker S, Azadian BS, Cream JJ. Minor skin surgery. Are prophylactic antibiotics ever needed for curettage? Acta Derm Venereol 1991;71:267-8.
95. CDC guidelines for prevention of surgical wound infections, 1985. Todays OR Nurse 1986;8:33-40.
96. Sriprachya-Anunt S, Fitzpatrick RE, Goldman MP, Smith SR. Infections complicating pulsed carbon dioxide laser resurfacing for photoaged facial skin. Dermatol Surg 1997;23:527-35.
97. Boss WK, Brand DA, Acampora D, et al. Effectiveness of prophylactic antibiotics in the outpatient treatment of burns. J Trauma 1985;25:224-7.
98. Dacso CC, Luterman A, Curreri PW. Systemic antibiotic treatment in burned patients. Surg Clin North Am 1987;67:57-68.
99. McManus WF, Goodwin CW, Mason AD Jr, Pruitt BA Jr. Burn wound infection. J Trauma 1981;21:753-6.
100. Timmons MJ. Are systemic prophylactic antibiotics necessary for burns? Ann R Coll Surg Engl 1983;65:80-2.
101. Waldorf HA, Kauvar AN, Geronemus RG. Skin resurfacing of fine to deep rhytides using a char-free carbon dioxide laser in 47 patients. Dermatol Surg 1995;21:940-6.
102. 2 laser resurfacing: avoiding pitfalls. Plast Reconstr Surg 1997;100:1855-66.
103. Beeson WH, Rachel JD. Valacyclovir prophylaxis for herpes simplex virus infection or infection recurrence following laser skin resurfacing. Dermatol Surg 2002;28:331-6.
104. Gilbert S, McBurney E. Use of valacyclovir for herpes simplex virus-1 (HSV-1) prophylaxis after facial resurfacing: a randomized clinical trial of dosing regimens. Dermatol Surg 2000;26:50-5.
105. Gilbert S. Improving the outcome of facial resurfacing-prevention of herpes simplex virus type 1 reactivation. J Antimicrob Chemother 2001;47 Suppl T1:29-34.
106. Perkins SW, Sklarew EC. Prevention of facial herpetic infections after chemical peel and dermabrasion: new treatment strategies in the prophylaxis of patients undergoing procedures of the perioral area. Plast Reconstr Surg 1996;98:427-33.
107. Fidler PE, Mackool BT, Schoenfeld DA, et al. Incidence, outcome, and long-term consequences of herpes simplex virus type 1 reactivation presenting as a facial rash in intubated adult burn patients treated with acyclovir. J Trauma 2002;53:86-9.
108. Sheridan RL, Schulz JT, Weber JM, et al. Cutaneous herpetic infections complicating burns. Burns 2000;26:621-4.
109. Duke D, Grevelink JM. Care before and after laser skin resurfacing. A survey and review of the literature. Dermatol Surg 1998;24:201-6.
110. Goldman BD. Herpes serology for dermatologists. Arch Dermatol 2000;136:1158-61.
111. Hayden FG, Himel HN, Heggers JP. Herpesvirus infections in burn patients. Chest 1994;106:15S-21S.
112. Nanni CA, Alster TS. Complications of carbon dioxide laser resurfacing. An evaluation of 500 patients. Dermatol Surg 1998;24:315-20.
113. Wall SH, Ramey SJ, Wall F. Famciclovir as antiviral prophylaxis in laser resurfacing procedures. Plast Reconstr Surg 1999;104:1103-8.
114. Whitley RJ, Kimberlin DW, Roizman B. Herpes simplex viruses. Clin Infect Dis 1998;26:541-53.
115. Alster TS, Nanni CA. Famciclovir prophylaxis of herpes simplex virus reactivation after laser skin resurfacing. Dermatol Surg 1999;25:242-6.
116. Bisaccia E, Scarborough D. Herpes simplex virus prophylaxis with famciclovir in patients undergoing aesthetic facial CO2 laser resurfacing. Cutis 2003;72:327-8.
117. Grazer FM, de Jong RH. Fatal outcomes from liposuction: census survey of cosmetic surgeons. Plast Reconstr Surg 2000;105:436-46.
118. Lehnhardt M, Homann HH, Druecke D, et al. [No problem with liposuction?]. Chirurg 2003;74:808-14.
119. Hanke CW, Coleman WP III. Morbidity and mortality related to liposuction. Questions and answers. Dermatol Clin 1999;17:899-902, viii.
120. Hanke CW, Bernstein G, Bullock S. Safety of tumescent liposuction in 15,336 patients. National survey results. Dermatol Surg 1995;21:459-62.
121. Housman TS, Lawrence N, Mellen BG, et al. The safety of liposuction: results of a national survey. Dermatol Surg 2002;28:971-8.
122. Platt MS, Kohler LJ, Ruiz R, et al. Deaths associated with liposuction: case reports and review of the literature. J Forensic Sci 2002;47:205-7.
123. Dillerud E. Suction lipoplasty: a report on complications, undesired results, and patient satisfaction based on 3511 procedures. Plast Reconstr Surg 1991;88:239-46.
124. Barillo DJ, Cancio LC, Kim SH, et al. Fatal and near-fatal complications of liposuction. South Med J 1998;91:487-92.
125. Beeson WH, Slama TG, Beeler RT, et al. Group A streptococcal fasciitis after submental tumescent liposuction. Arch Facial Plast Surg 2001;3:277-9.
126. Bello EF, Posalski I, Pitchon H, Bayer AS. Fasciitis and abscesses complicating liposuction. West J Med 1988;148:703-6.
127. Heitmann C, Czermak C, Germann G. Rapidly fatal necrotizing fasciitis after aesthetic liposuction. Aesthetic Plast Surg 2000;24:344-7.
128. Nagelvoort RW, Hulstaert PF, Kon M, Schuurman AH. [Necrotising fasciitis and myositis as serious complications after liposuction]. Ned Tijdschr Geneeskd 2002;146:2430-5.
129. Dajani AS, Bisno AL, Chung KJ, et al. Prevention of bacterial endocarditis. Recommendations by the American Heart Association. JAMA 1990;264:2919-22.
130. Bayliss R, Clarke C, Oakley CM, et al. The microbiology and pathogenesis of infective endocarditis. Br Heart J 1983;50:513-9.
131. Durack DT. Prophylaxis of infective endocarditis. In: Mandell GL, Bennett JE, Dolin R. editors. Principles and practice of infectious diseases. New York: Churchill Livingstone; 1990. p. 716-21.
132. Griffin MR, Wilson WR, Edwards WD, et al. Infective endocarditis. Olmsted County, Minnesota, 1950 through 1981. JAMA 1985;254:1199-202.
133. Spelman DW, Weinmann A, Spicer WJ. Endocarditis following skin procedures. J Infect 1993;26:185-9.
134. Babcock MD, Grekin RC. Antibiotic use in dermatologic surgery. Dermatol Clin 2003;21:337-48.
135. Carmichael AJ, Flanagan PG, Holt PJ, Duerden BI. The occurrence of bacteraemia with skin surgery. Br J Dermatol 1996;134:120-2.
136. Halpern AC, Leyden JJ, Dzubow LM, McGinley KJ. The incidence of bacteremia in skin surgery of the head and neck. J Am Acad Dermatol 1988;19:112-6.
137. Sabetta JB, Zitelli JA. The incidence of bacteremia during skin surgery. Arch Dermatol 1987;123:213-5.
138. Wilson WR, Van Scoy RE, Washington JA. Incidence of bacteremia in adults without infection. J Clin Microbiol 1976;2:94-5.
139. Zack L, Remlinger K, Thompson K, Massa MC. The incidence of bacteremia after skin surgery. J Infect Dis 1989;159:148-50.
140. Everett ED, Hirschmann JV. Transient bacteremia and endocarditis prophylaxis. A review. Medicine (Baltimore) 1977;56:61-77.
141. Dajani AS, Bawdon RE, Berry MC. Oral amoxicillin as prophylaxis for endocarditis: what is the optimal dose? Clin Infect Dis 1994;18:157-60.
142. Parker RH, Fossieck BE Jr. Intravenous followed by oral antimicrobial therapy for staphylococcal endocarditis. Ann Intern Med 1980;93:832-4.
143. Fluckiger U, Francioli P, Blaser J, et al. Role of amoxicillin serum levels for successful prophylaxis of experimental endocarditis due to tolerant streptococci. J Infect Dis 1994;169:1397-400.
144. Rouse MS, Steckelberg JM, Brandt CM, et al. Efficacy of azithromycin or clarithromycin for prophylaxis of viridans group streptococcus experimental endocarditis. Antimicrob Agents Chemother 1997;41:1673-6.
145. Garlando F, Tauber MG, Luthy R. [Endocarditis prophylaxis with amoxicillin, clindamycin or erythromycin? Serum bacteriostatic and bactericidal effect against Streptococcus viridans]. Dtsch Med Wochenschr 1988;113:1087-91.
146. American Dental Association, American Academy of Orthopaedic Surgeons. Advisory statement. Antibiotic prophylaxis for dental patients with total joint replacements. J Am Dent Assoc 1997;128:1004-8.
147. Chiesa R, Astore D, Frigerio S, et al. Vascular prosthetic graft infection: epidemiology, bacteriology, pathogenesis and treatment. Acta Chir Belg 2002;102:238-47.
148. Vinchon M, Lemaitre MP, Vallee L, Dhellemmes P. Late shunt infection: incidence, pathogenesis, and therapeutic implications. Neuropediatrics 2002;33:169-73.
149. Wilson SE. New alternatives in management of the infected vascular prosthesis. Surg Infect (Larchmt) 2001;2:171-5.
150. Bayston R. Epidemiology, diagnosis, treatment, and prevention of cerebrospinal fluid shunt infections. Neurosurg Clin N Am 2001;12:703-8, viii.
151. Rahlf G, Urban P, Bohle RM. Morphology of healing in vascular prostheses. Thorac Cardiovasc Surg 1986;34:43-8.
152. Jones L, Braithwaite BD, Davies B, et al. Mechanism of late prosthetic vascular graft infection. Cardiovasc Surg 1997;5:486-9.
153. Kaebnick HW, Bandyk DF, Bergamini TW, Towne JB. The microbiology of explanted vascular prostheses. Surgery 1987;102:756-62.
154. Keller JD, Falk J, Bjornson HS, et al. Bacterial infectibility of chronically implanted endothelial cell-seeded expanded polytetrafluoroethylene vascular grafts. J Vasc Surg 1988;7:524-30.
155. Goeau-Brissonniere O, Leport C, Lebrault C, et al. Antibiotic prophylaxis of late bacteremic vascular graft infection in a dog model. Ann Vasc Surg 1990;4:528-32.